Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children

DSpace/Manakin Repository

Show simple item record Karema, C. en_US Fanello, C. I. en_US Van Overmeir, C. en_US Van Geertruyden, J. P. en_US van Doren, W. en_US Ngamije, D. en_US D'Alessandro, U. en_US 2007-12-06T14:33:40Z 2007-12-06T14:33:40Z 2006 en_US
dc.identifier.issn 0035-9203 en_US
dc.identifier.other ITG-P3B en_US
dc.identifier.other ITG-P4A en_US
dc.identifier.other ITG-PLA en_US
dc.identifier.other PARAS en_US
dc.identifier.other U-MALAR en_US
dc.identifier.other JIF en_US
dc.identifier.other DOI en_US
dc.identifier.other ABSTRACT en_US
dc.description.abstract In Rwanda, amodiaquine+sulfadoxine/pyrimethamine (AQ+SP) is the current first-line treatment for malaria, introduced in 2001 as an interim strategy before the future deployment of an artemisinin-based combination treatment (ACT). Dihydroartemisinin/piperaquine (DHA-PQP) is a new co-formulated and well tolerated ACT increasingly used in Southeast Asia where it has proved to be highly effective against Plasmodium falciparum malaria. We tested the efficacy, safety and tolerability of DHA-PQP in children with uncomplicated P. falciparum malaria. A randomised, open trial was carried out in 2003-2004. Seven hundred and sixty-two children aged 12-59 months with uncomplicated P. falciparum malaria were randomly allocated to one of the following treatments: amodiaquine+artesunate; AQ+SP; or DHA-PQP. Patients were followed-up until Day 28 after treatment. Adverse events and clinical and parasitological outcomes were recorded. Children treated with DHA-PQP or AQ+AS had a significantly higher cure rate compared with those treated with amodiaquine+sulfadoxine/pyrimethamine (95.2% and 92.0% vs. 84.7%, respectively). Parasite clearance was significantly faster in children treated with DHA-PQP and AQ+AS compared with those treated with amodiaquine+sulfadoxine/pyrimethamine. The frequency of adverse events was significantly lower in patients treated with DHA-PQP than in those treated with combinations containing amodiaquine. A 3-day treatment with DHA-PQP proved to be efficacious with a good safety and tolerability profile and could be a good candidate for the next first-line treatment. en_US
dc.language English en_US
dc.publisher Elsevier
dc.subject Protozoal diseases en_US
dc.subject Malaria en_US
dc.subject Plasmodium falciparum en_US
dc.subject Drug therapy en_US
dc.subject Piperaquine en_US
dc.subject Amodiaquine en_US
dc.subject Sulfadoxine-pyrimethamine en_US
dc.subject Artemisinin combination therapies (ACT) en_US
dc.subject Efficacy en_US
dc.subject Treatment outcomes en_US
dc.subject Safety en_US
dc.subject Adverse effects en_US
dc.subject Adverse effects en_US
dc.subject Rwanda en_US
dc.subject Africa, Central en_US
dc.title Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children en_US
dc.type Article en_US
dc.citation.issue 12 en_US
dc.citation.jtitle Transactions of the Royal Society of Tropical Medicine and Hygiene en_US
dc.citation.volume 100 en_US
dc.citation.pages 1105-1111 en_US Amsterdam
dc.citation.jabbreviation Trans R Soc Trop Med Hyg en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record